Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Progress of tumour biopsies throughout the study

From: Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast

  Patients (n)
Patients randomised 250
   To ddAT + tamoxifen 122
   To ddAT – tamoxifen 128
Data on pCR available 247
   No breast cancer 1
   Chemotherapy refused 1
   Surgery refused 1
Core biopsies available and evaluable 196
   Not available 35
   No tissue on block 6
   Non-characteristic tissue 2
   No tumour tissue on block 8
Results available for multivariate analysis (without clinical response after 2 cycles) 193
Multivariate analysis data missing for:  
Menopausal stage 0
Tumour size 0
Nodal status 0
Grade 2
ER 0
PgR 0
Ki-67 0
HER2 2
p53 0
bcl-2 0
Results available for multivariate analysis (with clinical response after 2 cycles) 181
Multivariate analysis data missing for clinical response after two cycles 12
  1. ddAT, dose-dense Adriblastin (Doxorubicin) and Taxotere (Docetaxel); ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; pCR, pathological complete remission; PgR, progesterone receptor.